Links to access each publication and its plain language summary can be found by clicking "Read more"

November 30, 2022

The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trial

Abstract Background REPRIEVE, the Randomized Trial to Prevent Vascular Events in HIV, is a multicenter, primary prevention trial evaluating whether a statin can prevent major cardiovascular […]
November 30, 2022

Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV

Abstract Objective To investigate relationships between Life’s Simple 7 (LS7), an assessment of cardiovascular health (CVH), and coronary plaque among people with HIV (PWH). Methods Coronary […]
September 27, 2022

Sex-Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation among People with HIV in the U.S.

Abstract Background Among people with HIV (PWH), sex-differences in presentations of atherosclerotic cardiovascular disease (ASCVD) may be influenced by differences in coronary plaque parameters, immune/inflammatory biomarkers, […]
September 1, 2022

Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV)

Abstract Background Cytomegalovirus (CMV) infection is thought to result in increased immune activation in people with human immunodeficiency virus (HIV, PWH). Although some data have linked […]
August 11, 2022

Diet in a Global Cohort of Adults with HIV at Low to Moderate Traditional Cardiovascular Disease Risk

Abstract Objective To characterize diet quality across a global cohort of people with HIV (PWH). Design Cross-sectional analysis. Methods Leveraging REPRIEVE data from baseline across five Global Burden […]
June 3, 2022

Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy

Abstract Background People with HIV (PWH) have subclinical coronary artery disease (CAD) despite low traditional atherosclerotic cardiovascular disease (ASCVD) risk scores. Coronary plaque in PWH presents […]
June 3, 2022

Asymptomatic SARS-CoV-2 Infection is Common among ART-treated People with HIV

Abstract Background Limited data are available regarding asymptomatic COVID-19 among people with HIV (PWH). Data on a representative subset of PWH enrolled in REPRIEVE, a global clinical trial […]
March 7, 2022

Geographical Differences in the Self-Reported Functional Impairment of People with HIV and Associations with Cardiometabolic Risk

Abstract Background We sought to explore multinational differences in functional status by Global Burden of Disease (GBD) regions in the REPRIEVE cohort. Methods REPRIEVE is a […]
March 3, 2022

Factors Associated with Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People with HIV on Antiretroviral Therapy

Abstract Background Among ART-treated people with HIV (PWH), persistent systemic immune activation contributes to atherogenesis, cardiovascular disease (CVD) events, and mortality. Factors associated with key immune […]
December 13, 2021

Prevalence and Correlates of Electrocardiographic Abnormalities in Adults with HIV: Insights from the REPRIEVE Trial

Abstract Background People with HIV (PWH) are at increased risk for cardiovasvular disease (CVD) and sudden cardiac death. Prior work has suggested an association between HIV […]
December 13, 2021

COVID-19 Vaccination Rates in a Global HIV Cohort

Abstract Little is known regarding COVID-19 vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates […]
December 13, 2021

Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus

Abstract Background Emerging data demonstrate that the use of integrase inhibitor (INSTI)-based antiretroviral treatment (ART) is associated with increased weight, but the cardiometabolic health consequences of […]
July 7, 2021

Cardiovascular Risk and Health Among People With HIV Eligible for Primary Prevention: Insights From the REPRIEVE Trial

Abstract Background In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and HIV-related factors may contribute to future CV events in persons with HIV […]
July 7, 2021

Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention

Key Points Question  What is the extent of coronary artery disease among people with well-controlled HIV and low to moderate risk of atherosclerotic cardiovascular disease (ASCVD), and […]
September 17, 2020

Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Co-Principal Investigators

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 […]
September 17, 2020

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial

Background: Patterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and contemporary trends are not well described. Methods: The REPRIEVE trial (Randomized Trial to […]
September 17, 2020

Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial

Background: Reproductive aging may contribute to cardiometabolic comorbid conditions. We integrated data on gynecologic history with levels of an ovarian reserve marker (anti-müllerian hormone [AMH)] to […]
September 17, 2020

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum

Abstract: Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are under-reported in HIV and cardiovascular […]
September 17, 2020

An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus

Background: Chronic kidney disease is a common comorbid condition among persons living with human immunodeficiency virus (PWH). We characterized baseline kidney function in the REPRIEVE (Randomized […]
September 17, 2020

Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE

Background: People with human immunodeficiency virus (PWH) are at risk for accelerated development of physical function impairment and frailty; both associated with increased risk of falls, […]
September 17, 2020

Myocardial Steatosis Among Antiretroviral Therapy–Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial

Background: People with human immunodeficiency virus (PWH) face increased risks for heart failure and adverse heart failure outcomes. Myocardial steatosis predisposes to diastolic dysfunction, a heart […]
September 17, 2020

Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination

Background: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is a multicenter, randomized, placebo-controlled trial, designed to test whether a statin medication can prevent […]
September 17, 2020

Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Background: Cardiovascular disease (CVD) is more frequent among people with HIV (PWH) and may relate to traditional and nontraditional factors, including inflammation and immune activation. A critical need […]
September 17, 2020

Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers

Background: The REPRIEVE Mechanistic Substudy (A5333s) represents the first large, randomized, CCTA-based assessment of the effects of a primary prevention strategy for CVD on high-risk CAD, […]